Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode… Read More ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

UC Santa Cruz deepens industry engagement to underscore its vital role in contributing basic research and tomorrow’s talent, convening its first international RNA biotech conference on August 18 ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce ...

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, ...

Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the ...

Scientists at the Department of Energy's Oak Ridge National Laboratory have created a platform that pinpoints genetic ...

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside. Read more on ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Researchers are increasingly using AI and biotechnology tools to better understand the ...

Welcome to Legend Biotech Second Quarter 2026 Earnings Call. [Operator Instructions] Please be advised that today's ...

Legend Biotech has frequently been at the center of takeover rumors, and the stock regularly spikes on speculation that it has received formal buyout bids. It stands out as one of the most uniquely ...